

Abstract #348

Clinical follow up of patients with multiple sclerosis 10 years after PDE5Is treatment for Erectile Dysfunction: a real life cohort study.

Thomas C¹, Kratiras Z², Samarinas M³, Diamantis G⁴, Konstantinidis C⁴

1. General Hospital of Corinth, Urology dpt, Corinth, Greece,

2. National & Kapodistrian University, Urology dpt Attiko Hospital, Athens, Greece,

3. General Hospital of Larissa, Urology dpt /General Hospital, Larissa, Greece,

4. National Rehabilitation Center, Urology and Neuro urology Unit/National Rehabilitation Center, Athens, Greece

Hypothesis / aims of study

Erectile Dysfunction (ED) is very common in patients suffering from Multiple Sclerosis (MS); the prevalence varies from 30% to almost 90%. Our aim was to study the adherence of MS patients to PDE5Is, in 10 years period.

Study design, materials and methods

119 MS patients suffering from ED that were treated with PDE5Is were evaluated in 2015. Concomitant cardiovascular diseases, hormonal and psychiatric disorders were excluded. Efficacy was evaluated with IIEF5 and SEP2&3 questions. We re-evaluate our data now in order to assess the adherence to PDE5Is, almost 10 years after.

Results and interpretation

10 years after we collected data from 94 patients out of the original 101 responders.

- From the **sildenafil** group, 20 out of 36 are still on, 5 on daily tadalafil, 1 on intra-cavernosal injections (ICI), 1 died, 3 were lost from follow up, 1 underwent a 3-piece inflatable penile prosthesis insertion, 2 stopped due to lack of sexual partner and 3 stopped due to MS progression.
- From the **varденаfil** group, 5/15 are still on, 2 on sildenafil, 2 on daily tadalafil, 1 on ICC, 3 without partner and 2 stopped due to progression.
- From the **avanafil** group, 4/8 responders are still on, 1 ion sildenafil, 1 on daily tadalafil, 1 on ICC and 1 stopped to progression.
- From the on **demand tadalafil** group, 7/18 are still on, 5 on daily tadalafil, 1 on sildenafil, 2 were lost from follow up, 1 on ICC, 1 without partner and 1 stopped due to progression.
- From **daily tadalafil** group, 10/24 are still on, 1 is dead, 1 on ICC, 6 on sildenafil on, 1 underwent penile prosthesis, 2 without partner, 3 stopped due to progression.

	START	RESPONDERS	10 YEARS AFTER	SILDENAFIL	VARDENAFIL	AVANAFIL	TADALAFIL OD	TADALAFIL	ICIs	IPP	RELO-CATED	OUT OF REACH	DIED	LACK OF PARTNER	PROGRESSION
SILDENAFIL	41	36	25	20	0	0	0	5	1	1	2	1	1	2	3
VARDENAFIL	19	15	10	2	5	0	0	2	1	0	0	0	0	3	2
AVANAFIL	9	8	6	1	0	4	0	1	1	0	0	0	0	0	1
TADALAFIL OD	22	18	13	1	0	0	7	5	1	0	1	1	0	1	1
TADALAFIL DAILY	28	24	16	6	0	0	0	10	1	1	0	0	1	2	3

Conclusions

After almost **10 years of follow up**, the majority of our MS patients remained on PDE5 inhibitors, either the one prescribed initially or a different one. The medication dropout rate, in our cohort, is approximately **24%**, while disease progression and lack of sexual partner were the major reasons for withdrawal.

References

1. Efficacy of PDE-5 inhibitors in erectile dysfunction due to multiple sclerosis Z. Kratiras, C Konstantinidis, C Thomas, P. Kartsaklis, K. Makarounis, K. Skriapas. The Journal of Sexual Medicine, Vol. 13, Issue 5, S145–S146 Published in issue: May 2016